Literature DB >> 29284203

Severe 5,10-methylenetetrahydrofolate reductase deficiency: a rare, treatable cause of complicated hereditary spastic paraplegia.

A Perna1, M Masciullo2, A Modoni1, E Cellini3, E Parrini3, E Ricci1, A M Donati4, G Silvestri1.   

Abstract

BACKGROUND AND
PURPOSE: Juvenile- or adult-onset forms of severe 5,10-methylenetetrahydrofolate reductase (MTHFR) deficiency manifesting as complicated hereditary spastic paraplegia have rarely been described.
METHODS: Two siblings with mental retardation developed a progressive spastic paraparesis in their late teens. Their diagnostic assessment included extensive neurophysiologic, neuroimaging and metabolic studies.
RESULTS: Brain magnetic resonance imaging showed occipital white matter alterations, and electromyography documented a mixed polyneuropathy. Severe hyperhomocisteinemia (>150 μmol/L) associated with the characteristic amino acid profile suggested a diagnosis of severe MTHFR deficiency, confirmed by MTHFR direct sequencing. Treatment with betaine and vitamins benefitted patients' symptoms and diagnostic features.
CONCLUSIONS: Severe MTHFR deficiency can be a rare, treatable cause of autosomal recessive complicated hereditary spastic paraplegia. Its screening should be part of the diagnostic flowchart for these disorders.
© 2017 EAN.

Entities:  

Keywords:  betain; cerebral white matter disease; complicated hereditary spastic paraplegia; hyperhomocysteinemia; severe 5,10-methylenetetrahydrofolate reductase deficiency

Mesh:

Substances:

Year:  2018        PMID: 29284203     DOI: 10.1111/ene.13557

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  7 in total

Review 1.  Inherited metabolic diseases mimicking hereditary spastic paraplegia (HSP): a chance for treatment.

Authors:  Hélio A G Teive; Carlos Henrique F Camargo; Eduardo R Pereira; Léo Coutinho; Renato P Munhoz
Journal:  Neurogenetics       Date:  2022-04-09       Impact factor: 3.017

2.  MTHFR Deficiency: A Potentially Treatable Cause of Adult-Onset Hereditary Spastic Paraparesis.

Authors:  Pachipala Sudheer; Ayush Agarwal; Ajay Garg; M V Padma Srivastava; Venugopalan Y Vishnu
Journal:  Ann Indian Acad Neurol       Date:  2022-01-12       Impact factor: 1.714

3.  Management of Hereditary Spastic Paraplegia: A Systematic Review of the Literature.

Authors:  Marta Bellofatto; Giovanna De Michele; Aniello Iovino; Alessandro Filla; Filippo M Santorelli
Journal:  Front Neurol       Date:  2019-01-22       Impact factor: 4.003

4.  Clinical, Biochemical, Radiological, and Genetic Profile of Patients with Homocysteine Remethylation Pathway Defect and Spastic Paraplegia.

Authors:  Hansashree Padmanabha; Rohan Mahale; Rita Christopher; Gautham Arunachal; Maya Bhat; Mahammad Samim Mondal; Ram Murthy Anjanappa; Ravindranadh Chowdhary Mundlamuri; Ravi Yadav; Seena Vengalil; Pooja Mailankody; Pavagada S Mathuranath; Sadanandavalli R Chandra; Atchayaram Nalini
Journal:  Ann Indian Acad Neurol       Date:  2021-12-14       Impact factor: 1.383

Review 5.  The Puzzle of Hereditary Spastic Paraplegia: From Epidemiology to Treatment.

Authors:  Arun Meyyazhagan; Haripriya Kuchi Bhotla; Manikantan Pappuswamy; Antonio Orlacchio
Journal:  Int J Mol Sci       Date:  2022-07-11       Impact factor: 6.208

6.  Adolescent/adult-onset homocysteine remethylation disorders characterized by gait disturbance with/without psychiatric symptoms and cognitive decline: a series of seven cases.

Authors:  Kai-Jie Chang; Zhe Zhao; Hong-Rui Shen; Qi Bing; Nan Li; Xuan Guo; Jing Hu
Journal:  Neurol Sci       Date:  2020-09-30       Impact factor: 3.830

7.  Targeted Therapies for Hereditary Peripheral Neuropathies: Systematic Review and Steps Towards a 'treatabolome'.

Authors:  Matthew J Jennings; Angela Lochmüller; Antonio Atalaia; Rita Horvath
Journal:  J Neuromuscul Dis       Date:  2021
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.